个人简介

2021.07—至今  湖北理工学院医学院，副教授，硕士生导师。

荣誉：黄石市优秀科技先进个人；湖北理工学院科研标兵。

代表性论文

1.Binbin Cheng#, Wei Wang#, Ting Liu, Hao   Cao, Wei Pan, Yao Xiao, Shuwen Liu*, Jianjun Chen*. Bifunctional small   molecules targeting PD-L1/CXCL12 as dual immunotherapy for cancer treatment.   Signal Transduct Target Ther., 2023, 8: 91-93.

2.Binbin Cheng, Yaru Shi, Chuxiao Shao,   Shuanghu Wang, Zhenhong Su, Jin Liu, Yingxing Zhou, Xiaoting Fei, Wei Pan*,   Jianjun Chen*, Yiyu Lu*, and Jian Xiao*. Discovery of Novel Heterotricyclic   Compounds as DNA-Dependent Protein Kinase (DNA-PK) Inhibitors with Enhanced   Chemosensitivity, Oral Bioavailability, and the Ability to Potentiate Cancer   Immunotherapy. J. Med. Chem. 2024, 67, 8, 6253–6267.

3. Binbin Cheng#, Wei Pan#, Yao Xiao#,   Zongbao Ding#, Yingxing Zhou, Xiaoting Fei, Jin Liu, Zhenhong Su*, Xiaopeng   Peng*, Jianjun Chen*. HDAC-targeting epigenetic modulators for cancer immunotherapy.   Eur J Med Chem., 2024, 265: 116129.

4.Zongbao Ding, Shuanghu Wang, Yaru Shi,   Xiaoting Fei, Binbin Cheng*, Yiyu Lu*, Jianjun Chen*. Discovery of Novel   D-(+)-Biotin-Conjugated Resorcinol Dibenzyl Ether-Based PD-L1 Inhibitors for   Targeted Cancer Immunotherapy. J Med Chem., 2023, 66: 10364–10380.

5.Zongbao Ding, Shuanghu Wang, Yaru Shi,   Xiaoting Fei, Binbin Cheng*, Yiyu Lu*, Jianjun Chen*. Discovery of Novel   D-(+)-Biotin-Conjugated Resorcinol Dibenzyl Ether-Based PD-L1 Inhibitors for   Targeted Cancer Immunotherapy. J Med Chem., 2023, 66: 10364–10380.

代表性科研项目

1.  国家自然科学基金青年项目(****4306)：用于肿瘤双免疫疗法的靶向PD-L1&CD73双功能小分子抑 制剂的构建和抗癌活性研究，主持。

2.  湖北省自然科学基金青年项目(2023AFB438)：基于精准靶向治疗策略的生物素偶联修饰联苯类 PD-L1 小分子抑制剂 的构建和抗癌活性研究，主持。

3.  湖北省重点实验室青年项目一项（SB202117）：新型靶向 PD-L1 和微管蛋白双靶点小分子抑制剂用于透明细胞肾细胞癌的合成以及作用机制研究，主持。

团队名称及成员

名称：用于肿瘤双免疫疗法的小分子创新药临床前关键技术研究科技创新团队

成员：程斌斌、 周颖星 、赵长虹、 张如岩、 杜晶晶